Trial Profile
Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Grapiprant (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Arrys Therapeutics
- 19 Feb 2021 Status changed from active, no longer recruiting to discontinued based on the totality of the generated combined safety and efficacy data in the interim period,the company decided to terminate the combination study in NSCLC patients. There are no subjectson study drug at this time or in the EOT Follow-up period.
- 22 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2020 Planned number of patients changed from 25 to 41.